WO2020014310A1 - Pansement avancé ayant une compression et une manipulation de fluide totale accrue - Google Patents

Pansement avancé ayant une compression et une manipulation de fluide totale accrue Download PDF

Info

Publication number
WO2020014310A1
WO2020014310A1 PCT/US2019/041133 US2019041133W WO2020014310A1 WO 2020014310 A1 WO2020014310 A1 WO 2020014310A1 US 2019041133 W US2019041133 W US 2019041133W WO 2020014310 A1 WO2020014310 A1 WO 2020014310A1
Authority
WO
WIPO (PCT)
Prior art keywords
layer
wound dressing
drape
adhesive
hydrophilic foam
Prior art date
Application number
PCT/US2019/041133
Other languages
English (en)
Inventor
Christopher B. Locke
Original Assignee
Kci Licensing, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kci Licensing, Inc. filed Critical Kci Licensing, Inc.
Publication of WO2020014310A1 publication Critical patent/WO2020014310A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive plasters or dressings
    • A61F13/0273—Adhesive bandages for winding around limb, trunk or head, e.g. cohesive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive plasters or dressings
    • A61F13/0203—Adhesive plasters or dressings having a fluid handling member
    • A61F13/0206—Adhesive plasters or dressings having a fluid handling member the fluid handling member being absorbent fibrous layer, e.g. woven or nonwoven absorbent pad, island dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive plasters or dressings
    • A61F13/0246—Adhesive plasters or dressings characterised by the skin adhering layer
    • A61F13/025—Adhesive plasters or dressings characterised by the skin adhering layer having a special distribution arrangement of the adhesive

Definitions

  • the present disclosure relates generally to a wound dressing.
  • the present disclosure relates more particularly to a wound dressing having a hydrophilic foam layer and a drape layer, wherein the drape layer extends beyond a perimeter of the hydrophilic foam layer and includes a plurality of adhesive zones and non-adhesive zones.
  • wound dressings include a central foam layer surrounded by an adhesive layer to maintain the position of the wound dressing.
  • the adhesive is too close to the wound bed and may cause additional damage to the patient’s peri- wound skin. Additionally, some commonly used adhesives may be detrimental to the patient upon removal of the wound dressing. It is therefore desirable to provide a wound dressing with minimal adhesives and more specifically with adhesives located remotely from the wound bed.
  • One implementation of the present disclosure is a wound dressing including a hydrophilic foam layer, a drape layer, and at least one adhesive zone.
  • the hydrophilic foam layer is configured to engage a wound bed and has a first side and a second side, wherein the second side is configured to face the wound bed.
  • the drape layer has a first side and a second side, wherein the second side faces the first side of the hydrophilic foam layer.
  • the drape layer extends beyond a perimeter of the hydrophilic foam layer.
  • the drape layer includes at least one adhesive zone disposed proximate opposite ends of the second side of the drape layer and a non-adhesive zone disposed between each adhesive zone and the foam layer, wherein the non-adhesive zones are substantially free of adhesives.
  • Another implementation of the present disclosure is a method of applying a wound dressing.
  • the method includes placing a hydrophilic foam layer on a wound surface, wherein the hydrophilic foam layer has a first side and a second side, the second side configured to face the wound surface.
  • the method further includes wrapping a first side of a drape layer around the patient limb, wherein the drape layer has a first side and a second side, the second side configured to face they hydrophilic foam layer.
  • the method further includes adhering a first adhesive zone on a first end of the drape layer to the patient limb distal from the wound surface.
  • the method further includes stretching the drape layer around the patient limb such that a second end of the drape layer overlaps the first end of the drape layer.
  • the method includes adhering a second adhesive zone on the second end of the drape layer to the first end of the drape layer, wherein all contact between the wound dressing and the patient limb is adhesive-free, except for the first adhesive zone.
  • FIG. 1 is a top view of a wound dressing, according to an exemplary embodiment.
  • FIG. 2 is a bottom view of the wound dressing of FIG. 1, according to an exemplary embodiment.
  • FIG. 3 is an exploded perspective view illustrating several layers of the wound dressing of FIGS. 1 and 2, according to an exemplary embodiment.
  • FIGS. 4A-4C show a method of applying the wound dressing of FIGS. 1 and 2, according to an exemplary embodiment.
  • FIG. 5 is a perspective view of the wound dressing of FIGS. 1 and 2, according to an exemplary embodiment.
  • a wound dressing with a drape layer and a hydrophilic foam layer is shown, according to exemplary embodiments.
  • the wound dressing of the exemplary embodiments has multiple layers including a hydrophilic foam layer and a drape layer.
  • the drape layer extends beyond a perimeter of the hydrophilic foam layer.
  • the drape layer has adhesive zones disposed on the ends of the drape layer to adhere the wound dressing to a patient surface, such as a limb.
  • the drape layer further includes non-adhesive zones between each adhesive zone and the hydrophilic foam layer that are free of adhesives.
  • the drape layer has limited adhesive zones disposed at opposite ends, such that the drape layer can be wrapped around and adhered to a patient surface, such as a limb.
  • the hydrophilic foam layer is placed over the wound bed, and the drape layer is placed over the hydrophilic foam layer.
  • the drape layer may extend in width around the hydrophilic foam layer, such as to provide a fluid seal about the hydrophilic foam layer.
  • the drape layer is then wrapped around the limb such that the first adhesive zone on a first end of the drape layer adheres to the limb on the opposite side of the wound and the second adhesive zone on a second end of the drape layer overlaps with and adheres to the first end of the drape layer so that the second adhesive zone adheres without contact to the patient’s skin.
  • the first adhesive zone may comprise a weaker adhesive than the second adhesive zone so as to prevent damage to the patient’s skin from the adhesive.
  • the first adhesive zone is only sufficiently tacky so as to permit the temporary placement of the drape layer until the second adhesive zone is wrapped and secured to the first end of the drape layer.
  • the second adhesive zone may comprise a stronger adhesive so as to adequately adhere the second end of the drape layer to the first end of the drape layer and maintain the position of and compression of the wound dressing.
  • non-adhesive zones of the drape layer are configured to be positioned nearest the wound bed, such as to avoid further damage to the wound bed or the peri- wound by an adhesive.
  • the wound dressing may be configured to stretch around and cause compression of the patient limb.
  • the compression of the patient limb may be between 18 mmHg and 24 mmHg.
  • the drape layer may have printed indicators which stretch and provide a visual and/or tactile indication of the level of compression of the wound dressing. This is intended to prevent unintended and/or inadvertently high levels of compression, which may cause patient discomfort and potential damage of the wound bed or peri-wound.
  • the drape layer may be substantially thick with a thickness of greater than 30 microns so as to provide a greater level of compression and tension to the patient. Such a high compression may assist in fluid movement, drawing the fluid through the hydrophilic foam layer to promote faster wound healing. Additionally, compression may lower the risk of edema within the wound.
  • the wound dressing may further include an absorbent layer.
  • the absorbent layer may be adhered to the hydrophilic foam layer to provide enhanced absorbency of the wound dressing.
  • the absorbent layer may be laminated to the hydrophilic foam layer via a fusible fiber.
  • the absorbent layer may take place in the form of an encapsulated super-absorbent or a printed absorbent structure printed onto the hydrophilic foam layer. Additional features and advantages of the wound dressing are described in greater detail below.
  • FIG. 1 is a top view of a wound dressing 100 as would be visible when wound dressing 100 is adhered to a surface (e.g, a patient’s skin).
  • FIG. 2 is a bottom view of wound dressing 100 showing the surface of wound dressing 100 configured to contact a wound.
  • the broken lines in FIGS.1-2 outline the layers of wound dressing 100 that are not visible in each view.
  • FIG. 3 is an exploded view illustrating several components and layers 102-106 of wound dressing 100.
  • FIGS. 4A-4C show a method of applying the wound dressing 100 to the patient limb.
  • FIG. 5 illustrates one embodiment of a perspective view of the wound dressing 100.
  • wound dressing 100 can be formed as a substantially flat sheet for topical application to wounds, or formed as a contoured dressing for application to body surfaces having high curvature.
  • the size and shape of wound dressing 100 can vary depending on the size of the wound to be dressed and its location.
  • the size of the hydrophilic foam layer of the wound dressing can range from approximately 1 cm 2 to 200 cm 2 , and more preferably from approximately 4 cm 2 to 100 cm 2 .
  • the drape layer may extend in width on either side of the hydrophilic foam layer between a range from approximately 10 mm to 20 mm in order to create a fluid seal about the wound bed, and may extend in length such that when wrapped around a patient’s limb, the drape layer may overlap itself by at least 20 mm.
  • the drape layer may be available in a variety of lengths, such that the length of the drape layer may be selected based on the demographic.
  • Other shapes and sizes of wound dressing 100 are also possible depending on the intended use. In other embodiments, wound dressing 100 may have a substantially convex or concave shape, or other customizable topography to adhere to wounds located on areas such as the knee or elbow.
  • Wound dressing 100 is shown to include (among other possible layers) a drape layer 102, an absorbent layer 104, and a hydrophilic foam layer 106. In some embodiments, wound dressing 100 may not include absorbent layer 104.
  • Drape layer 102 is shown to include a plurality of adhesive zones 112-114 located on opposite ends of the drape layer 102. In the embodiments shown in FIGS. 4A-4C, wound dressing 100 is applied for use in connection with a wound bed 134.
  • hydrophilic foam layer 106 covers the wound bed 134 and peri-wound 136, while drape layer 102 extends around the patient limb 128 to adhere to a distal side 132 of the patient limb 128.
  • Drape Laver covers the wound bed 134 and peri-wound 136
  • wound dressing 100 includes a drape layer 102.
  • Drape layer 102 is shown to include a first side 116 and a second side 118 opposite first side 116. Second side 118 is configured to face a wound. When wound dressing 100 is applied to a wound, first side 116 faces away from the wound whereas second side 118 faces towards the wound.
  • Drape layer 102 attaches over absorbent layer 104 and hydrophilic foam layer 106. In some embodiments, in the absence of absorbent layer 104, drape layer 102 is laminated to hydrophilic foam layer 106 via a fusible fiber. Drape layer 102 can be bonded to hydrophilic foam layer 106, for example, by an adhesive or by radiation cross-linking.
  • drape layer 102 is bonded to the hydrophilic foam layer 106 by urethane or urea linkages. This can be achieved by applying drape layer 102 to hydrophilic foam layer 106 (substantially without mixing) before polyurethane curing is complete. In still other embodiments, drape layer 102 may be substantially free of bonding to either the absorbent layer 104 or the hydrophilic foam layer 106.
  • drape layer 102 is a thin layer of polyurethane film.
  • a suitable material for drape layer 102 is the polyurethane film known as
  • drape layer 102 includes a continuous layer of a high-density blocked polyurethane foam that is predominantly closed cell. Drape layer 102 may have a thickness in the range of 10 pm to 100 pm, preferably in the range of 25 pm to 50 pm. In some embodiments, drape layer 102 has a thickness of approximately 30 pm.
  • Drape layer 102 may be substantially permeable to liquid and moisture vapor.
  • drape layer 102 may be permeable to both water vapor and liquid water such as wound exudate. Such permeability is intended to facilitate or enhance a hydrophilic gradient from the wound bed 134, through the wound dressing 100, and to the surrounding atmosphere to promote evaporation of wound fluid exudate.
  • drape layer 102 is impermeable to bacteria and other microorganisms.
  • drape layer 102 is configured to wick moisture from hydrophilic foam layer 106 and absorbent layer 104 to first side 116 of drape layer 118, such that it may evaporate into the atmosphere.
  • drape layer 102 may be substantially hydrophilic and have a high moisture vapor transmission rate, such as to permit evaporation of would exudate/fluid from first side 116 of drape layer
  • a central portion of drape layer 102 is substantially free of adhesives, such as second side 118 of drape layer 102 is not adhered to hydrophilic foam layer 106 or absorbent layer 104. Rather, drape layer 102 may optionally be laminated to hydrophilic foam layer 106 or absorbent layer 104 using a fusible fiber. In still other embodiments, drape layer 102 may be free of any type of bonding to either hydrophilic foam layer 106 or absorbent layer 104, allowing for greater total fluid handling and conformability of wound dressing 100.
  • the perimeter of drape layer 102 extends beyond (e.g., circumscribes) the perimeter of absorbent layer 104 and hydrophilic foam layer 106 to provide a margin for wound dressing 100 (e.g., as an“island” dressing) to attach to the patient limb 128.
  • drape layer 102 may extend in width beyond absorbent layer 104 and hydrophilic foam layer 106 by a distance between 10 mm to 20 mm, such that drape layer 102 forms a fluid seal about the wound dressing 100.
  • drape layer 102 extends in length beyond absorbent layer 104 and hydrophilic foam layer 106 such that a first end 108 and a second end of drape layer 102 may be configured to overlap when drape layer 102 is wrapped around a patient limb 128. In some embodiments, after wrapping of the drape layer 102 around patient limb 128, first end 108 and second end 110 of drape layer 102 may overlap by 10 mm to 20 mm. In other embodiments, drape layer 102 may be available in a variety of sizes of varying lengths such as to allow wound dressing 100 to be customizable for various patient demographics.
  • drape layer 102 includes a plurality of adhesive zones 112-114 on second side 118.
  • a first adhesive zone 112 is located at the first end 108 of drape layer 102 on second side 118.
  • a second adhesive zone 114 is located at the second end 110 of drape layer 102 on second side 118.
  • the first adhesive zone 112 and the second adhesive zone 114 exist within a range between 5% to 10% of each end 108-110 of second side 118 of drape layer.
  • second side 118 of drape layer 102 is substantially free of adhesives in the area existing between first adhesive zone 112 and second adhesive zone 114.
  • an adhesive may be applied to first adhesive zone 112 and second adhesive zone 114 in a continuous manner, so as to form a continuous area of adhesive within each adhesive zone 112-114.
  • the adhesive within each adhesive zone 112-114 may be non-continuous, such that the adhesive forms a pattern on second side 118 of drape layer 102.
  • first adhesive zone 112 is configured to adhere directly to a patient limb 128 on a distal side 132 (e.g., distal from the wound bed 134).
  • first adhesive zone 112 may comprise a coating of a gentle adhesive, such as silicone.
  • second adhesive zone adheres to first end 108.
  • second adhesive zone 114 may be configured to provide a stronger attachment than first adhesive zone 112.
  • Second adhesive zone 114 may comprise a coating of at least one adhesive including silicone, acrylic thermoplastic elastomer, and polyurethane gel.
  • first adhesive zone 112 and second adhesive zone 114 may comprise substantially the same adhesive to enable ease of use and reduce the risk of misuse of wound dressing 100.
  • first adhesive zone 112 and second adhesive zone 114 may comprise liners (e.g. peelable, removable, etc.) to protect the adhesives and which may be removed prior to application of wound dressing 100.
  • drape layer 102 may be placed over, and form a seal around, absorbent layer 104 and hydrophilic foam layer 106.
  • a central portion of drape layer 102 may align with the wound bed 124 on a proximal side 130 of patient limb 128.
  • first adhesive zone 112 on first end 108 of drape layer 102 may be wrapped around the patient limb 128, such that first adhesive zone 112 extends to the distal side 132 of patient limb 128.
  • First adhesive zone may then adhere to the distal side 132 of patient limb 128.
  • drape layer 102 may then be stretched, such that second end 110 extends, in the opposite direction of first end 108, towards the distal side 132 of patient limb 128.
  • drape layer 102 may comprise a plurality of printed indicators to provide a visual and tactile indication of the level of compression that will be applied to the patient limb 128 upon stretching of drape layer 102.
  • Second adhesive zone may then adhere to first end 108 of drape layer 102, such that first end 108 and second end 110 substantially overlap. In some embodiments, first end 108 and second end 110 may overlap by at least 20 mm.
  • first side 116 of drape layer 102 may have a plurality of printed indicators or markers to provide a visual indication of the level of compression of drape layer 102. This is intended to provide an indication to a caregiver as to how much tension to apply to the wound dressing 100 upon application to a patient limb 128 and to avoid excessive compression to the patient limb 128 which may cause additional damage to the existing wound.
  • the printed indicators may be in any shapes such as circles, squares, triangles, hexagons, hoops/halos, stars, crosses, a range of lines, or any combination of shapes.
  • the printed indicators may be printed such that they are substantially evenly distributed on first side 116.
  • the printed indicators may be printed in an uneven (e.g., non-uniform, random, etc.) pattern on first side 116.
  • the printed indicators are arranged in a non-contiguous manner (i.e. isolated, separated, spaced-apart, non-touching, etc.) so that a region remains between each indicator to preserve flexibility of wound dressing 100.
  • the printed indicator may be aligned with well-known clinical practice to achieve a compression force of approximately 18 mmHg to 24 mmHg of the wound dressing 100 surrounding patient limb 128.
  • a particular spacing between indicators may correspond to a certain level of compression, which may also be printed on the drape layer 102.
  • drape layer 102 may further be printed with thermochromic inks to as to enable the detection of evaporation of wound fluid exudate from first side 116 of drape layer 102.
  • the thermochromic inks of drape layer 102 may further be configured to detect an elevated temperature of the patient limb 128, which may be an indication of infection of wound bed 134 or periwound 136.
  • wound dressing 100 includes an absorbent layer 104.
  • Absorbent layer 104 is shown to include a first side 120 and a second side 122. When wound dressing 100 is applied to a wound, first side 120 faces away from the wound whereas second side 122 faces towards the wound. In some embodiments, first side 120 of absorbent layer 104 contacts second side 118 of drape layer 102. Similarly, second side 122 of absorbent layer 104 may contact a first side 124 of hydrophilic foam layer 106. In some embodiments, absorbent layer 104 is configured to wick moisture from hydrophilic foam layer 106 and distribute the moisture across first side 120. In some embodiments, absorbent layer 104 is encapsulated between hydrophilic foam layer 106 and drape layer 102. In other
  • second side 122 of absorbent layer 104 may be laminated or otherwise adhered to first side 124 of hydrophilic foam layer 106. In some embodiments, second side 122 of absorbent layer 104 may be laminated via a fusible fiber to first side 124 of hydrophilic foam layer 106.
  • absorbent layer 104 includes a hydrogel or hydrogel composition.
  • hydrogels and hydrogel compositions which can be used to form absorbent layer 104 are described in detail in U.S. Patent No. 8,097,272 issued January 17, 2012, U.S. Patent No. 8,664,464 issued March 4, 2014, and U.S. Patent No. 8,058,499 issued November 15, 2011. The entire disclosure of each of these patents is incorporated by reference herein.
  • Absorbent layer 104 may be formed from a polyurethane that entraps water to form a gel.
  • absorbent layer 104 is substantially continuous and/or substantially non-porous or non-foamed.
  • Absorbent layer 104 may include a flexible plasticized hydrophilic polymer matrix having a substantially continuous internal structure.
  • absorbent layer 104 includes a plurality of one or more cellulosic gelling fibers including carboxymethyl cellulose, carboxyethl cellulose, hydroxy ethyl cellulose, hydro xypropyl cellulose, hydro xypropyllmethyl cellulose, or cellulose ethyl sulphonate.
  • absorbent layer 104 includes a nonwoven hydrofiber material.
  • absorbent layer 104 includes one or more of a plurality of reinforcing fibers comprising a polyurethane gel, an amide polymer, an olefin polymer, an ester polymer, or a modified acrylamide polymer.
  • the material, formulation, and size of absorbent layer 104 may be determined based on desired fluid handling requirements of wound dressing 100.
  • absorbent layer 104 may be in the form of a plurality of superab sorbent projections printed or otherwise adhered to first side 124 of hydrophilic foam layer 106.
  • superabsorbent projections may be formed from or otherwise include a superabsorbent polymer in the form of granules.
  • the superab sorbent polymer may include Luquasorb 1160 or 1161, such as may be commercially available from BASF.
  • the granules may be contained in a water soluble carrier polymer.
  • the water soluble carrier polymer is polyvinylpyrrolidone(PVP).
  • the superab sorbent polymer of the superab sorbent projections 108 and the water soluble polymer may be formed into a slurry or a suspension using an organic solvent.
  • the organic solvent may include propanone or propanol, and may aid in delivery of the superabsorbent projections to the first side 124 of hydrophilic foam layer 106.
  • a plasticizer may be added to the slurry.
  • the plasticizer may be water.
  • the slurry to form the superabsorbent projections may have a formulation of 20 parts by mass of PVP, 10 parts by mass of a superab sorbent polymer, 1 part by mass of glycerol, and 100 parts by mass of propanone.
  • 1 part to 2 parts by mass of water may be added to the slurry mixture.
  • a water soluble polymer superabsorbent precursor such as acrylic acid or 2-acrylamido-2-methyl-propanesulfonic acid (AMPS), with suitable UV curing additives, may replace the superabsorbent polymer.
  • AMPS 2-acrylamido-2-methyl-propanesulfonic acid
  • Such a precursor may be a relatively low viscosity solution and can be printed onto elastic foam layer 106 and exposed to UV light to form a soft gel, eliminating the need for a plasticizer.
  • the water soluble polymer superabsorbent precursor may be similar to that used for preparing hydrogel coatings.
  • the slurry mixture is applied to first side 124 of hydrophilic foam layer 106 to form superab sorbent projections.
  • the slurry may be applied to hydrophilic foam layer 106 through standard printing methods, such as silk screen printing, gravure printing, or by x-y plotter printing.
  • Superabsorbent projections may be in any non contiguous shapes such as circles, squares, hexagons, hoops/halos, stars, crosses, a range of lines, or any combination of shapes.
  • Superabsorbent projections may be printed such that they are substantially evenly distributed on first side 124 of hydrophilic foam layer 106. In other embodiments, superab sorbent projections may be printed in an uneven (e.g.
  • superabsorbent projections are arranged in a non-contiguous manner (i.e. isolated, separated, spaced-apart, non-touching, etc.) so that a region remains between superab sorbent projections to preserve flexibility of wound dressing 100.
  • superab sorbent projections may include a flexible plasticized hydrophilic polymer matrix having a substantially continuous internal structure.
  • Superabsorbent projections may be configured to swell upon absorption of wound exudate fluid from wound bed 134 to provide a visual indication of which portion of wound dressing 102 has absorbed wound exudate fluid. In some embodiments, superabsorbent projections may be configured to change color to provide a further visual indication as to when fluid has been absorbed. Superabsorbent projections may be more hydrophilic than hydrophilic foam layer 106 such that they assist in wicking fluid from the second side 126 of hydrophilic foam layer 106 towards the first side 124.
  • wound dressing 100 includes a hydrophilic foam layer 106.
  • Hydrophilic foam layer 106 is shown to include a first side 124 and a second side 126 opposite first side 124. Second side 126 is configured to face and contact the wound.
  • first side 124 faces away from the wound whereas second side 126 faces towards the wound.
  • hydrophilic foam layer 106 and absorbent layer 104 cover both the wound bed 134 and the periwound 136.
  • hydrophilic foam layer 106 and absorbent layer 104 may lie entirely within the confines of wound bed 134, such that only drape layer 102 extends beyond and contacts the periwound 136.
  • first side 124 of hydrophilic foam layer 106 contacts second side 122 of absorbent layer 104. In other embodiments, in the absence of absorbent layer 104, first side of hydrophilic foam layer 106 contacts second side 118 of drape layer 102. In some embodiments, first side 124 of hydrophilic foam layer 106 is laminated via a fusible fiber to second side 118 of drape layer 102. Alternatively, first side 124 of hydrophilic foam layer 106 may be in contact with second side 118 of drape layer 102 without the use of adhesive.
  • Hydrophilic foam layer 106 may comprise a polyurethane foam or a polyethylene foam.
  • hydrophilic foam layer 106 includes a flexible plasticized hydrophilic polymer matrix having an internal cellular structure.
  • hydrophilic foams which can be used to make hydrophilic foam layer 106 are described in detail in U.S. Patent no. 8,097,272 issued January 17, 2012, U.S. Patent No. 8,664,464 issued March 4, 2014, and U.S. Patent No. 8,058,499 issued November 15, 2011. The entire disclosure of each of these patents is incorporated by reference herein. In other
  • hydrophilic foam layer 106 may be formed from aromatic or aliphatic precursors.
  • hydrophilic foam layer 106 may provide enhanced absorbency for liquid exudate. This is because the porous structure of the foam provides for rapid uptake of liquid exudate.
  • hydrophilic foam layer 106 includes an antimicrobial agent or other active agents to promote effective wound healing.
  • active materials may include antimicrobial silver, silver oxidized regenerated cellulose (ORC) (e.g., approximately 25 wt% ionically bonded silver), polyhexamethylene biguanide (PHMB), nosteroidal anti-inflammatory drugs such as acetaminophen, steroids, anti inflammatory cytokines, anesthetics, antimicrobial agents such as penicillin or streptomycin, antiseptics such as chlorhexidine, growth factors such as fibroblast growth factor (FGF), a platelet derived growth factor (PDGF), or an epidermal growth factor (EGF), and other therapeutic agents, individually or in any combination.
  • ORC silver oxidized regenerated cellulose
  • PHMB polyhexamethylene biguanide
  • nosteroidal anti-inflammatory drugs such as acetaminophen, steroids, anti inflammatory cytokines, anesthetics
  • antimicrobial agents such as
  • any active material may be loaded at a level of from about 10 wppm to about 10 wt% of the layer in which it is present, for example, from about 50 wppm to about 5 wt% or from about 100 wppm to about 1 wt%.
  • the active material may be contained within a thin film on second side 126 of hydrophilic foam layer 106 or may be distributed within hydrophilic foam layer 106.
  • wound dressing 100 has multiple advantages over previous wound dressings.
  • Wound dressing 100 is both soft and
  • Wound dressing 100 is substantially free of adhesive other than the small adhesive zones of the drape layer 102, which provides a no trauma dressing application and removal process. Further, wound dressing 100 is configured to provide quantifiable indication of a localized compression of the wound to reduce edema while retaining the position of the wound dressing 100. Wound dressing 100 is intended to be a simple to use and low cost approach to providing compression promoting wound healing, while providing improved observation of the wound dressing 100 such that a caregiver may be able to monitor the wound bed 134 and periwound 136 for signs of infection. Configuration of Exemplary Embodiments

Abstract

Un pansement comprend une couche de mousse hydrophile et une couche de drapé. La couche hydrophile est conçue pour venir en prise avec un lit de plaie et a un premier côté et un second côté, le second côté étant conçu pour faire face au lit de plaie. La couche de drapé a également un premier côté et un second côté, le second côté étant conçu pour faire face au premier côté de la couche de mousse hydrophile, la couche de drapé s'étendant au-delà d'un périmètre de la couche de mousse hydrophile. La couche de drapé a au moins une zone adhésive disposée entre des extrémités opposées proches du second côté de la couche de drapé et une zone non adhésive disposée entre chaque zone adhésive et la couche de mousse, les zones non adhésives étant sensiblement exemptes d'adhésifs.
PCT/US2019/041133 2018-07-13 2019-07-10 Pansement avancé ayant une compression et une manipulation de fluide totale accrue WO2020014310A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697755P 2018-07-13 2018-07-13
US62/697,755 2018-07-13

Publications (1)

Publication Number Publication Date
WO2020014310A1 true WO2020014310A1 (fr) 2020-01-16

Family

ID=67441758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/041133 WO2020014310A1 (fr) 2018-07-13 2019-07-10 Pansement avancé ayant une compression et une manipulation de fluide totale accrue

Country Status (1)

Country Link
WO (1) WO2020014310A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116884B2 (en) 2010-12-08 2021-09-14 Convatec Technologies Inc. Integrated system for assessing wound exudates
WO2021188185A1 (fr) * 2020-03-18 2021-09-23 Compression Dynamics, LLC Vêtements, kits, systèmes et procédés de pansement
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
US11241339B2 (en) 2011-11-29 2022-02-08 Convatec Inc. Perforated binder for laminated wound dressing
US11241525B2 (en) 2010-12-08 2022-02-08 Convatec Technologies Inc. Wound exudate monitor accessory
US11266774B2 (en) 2016-07-08 2022-03-08 Convatec Technologies Inc. Fluid collection apparatus
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing
US11452808B2 (en) 2016-07-08 2022-09-27 Convatec Technologies Inc. Fluid flow sensing
US11458044B2 (en) 2008-09-29 2022-10-04 Convatec Technologies Inc. Wound dressing
US11583430B2 (en) 2011-09-02 2023-02-21 Convatec Ltd. Skin contact material
US11596554B2 (en) 2016-07-08 2023-03-07 Convatec Technologies Inc. Flexible negative pressure system
US11628093B2 (en) 2008-05-08 2023-04-18 Convatec Technologies, Inc. Wound dressing
US11723808B2 (en) 2016-03-30 2023-08-15 Convatec Technologies Inc. Detecting microbial infections in wounds
US11740241B2 (en) 2016-03-30 2023-08-29 Synovo Gmbh Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1280631A (en) 1968-07-09 1972-07-05 Smith & Nephew Adhesive materials
US4334530A (en) * 1980-09-12 1982-06-15 Hassell Donald S Indicia-bearing adhesive bandages
WO2008082444A2 (fr) * 2006-10-03 2008-07-10 Arsenal Medical, Inc. Articles et procédés pour la réparation de tissus
US20110125183A1 (en) * 2009-11-24 2011-05-26 Circaid Medical Products Graduated Compression Device for the Treatment of Circulatory Disorders
US8058499B2 (en) 2001-11-23 2011-11-15 Systagenix Wound Management (Us), Inc. Absorbent wound dressing containing a hydrogel layer
US8097272B2 (en) 2000-12-07 2012-01-17 Systagenix Wound Management (Us), Inc. Layered materials for use as wound dressings
WO2013059600A1 (fr) * 2011-10-20 2013-04-25 Eaves Felmont Revêtement amovible et emballage interactif
US20130123728A1 (en) * 2011-11-15 2013-05-16 Kci Licensing, Inc. Medical dressings, systems, and methods with thermally-enhanced vapor transmissions
US8664464B2 (en) 2002-12-12 2014-03-04 Systagenix Wound Management (Us), Inc. Absorbent multilayer hydrogel wound dressings
US20140236112A1 (en) * 2011-09-26 2014-08-21 Bsn Medical Gmbh Wound dressing
US8844158B2 (en) * 2008-12-19 2014-09-30 Iqtex Patentverwaltung Ug Super absorber polymer felt and method for the production thereof
US20150119833A1 (en) * 2013-10-30 2015-04-30 Kci Licensing, Inc. Dressing with differentially sized perforations
WO2017214090A1 (fr) * 2016-06-06 2017-12-14 Elwha Llc Systèmes et procédés de surveillance de la compression à l'aide de bandages de compression à éléments électroniques étirables
US20170367899A1 (en) * 2015-01-19 2017-12-28 Presscise Ab A compression garment for provision of an adjustable pressure

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1280631A (en) 1968-07-09 1972-07-05 Smith & Nephew Adhesive materials
US4334530A (en) * 1980-09-12 1982-06-15 Hassell Donald S Indicia-bearing adhesive bandages
US8097272B2 (en) 2000-12-07 2012-01-17 Systagenix Wound Management (Us), Inc. Layered materials for use as wound dressings
US8058499B2 (en) 2001-11-23 2011-11-15 Systagenix Wound Management (Us), Inc. Absorbent wound dressing containing a hydrogel layer
US8664464B2 (en) 2002-12-12 2014-03-04 Systagenix Wound Management (Us), Inc. Absorbent multilayer hydrogel wound dressings
WO2008082444A2 (fr) * 2006-10-03 2008-07-10 Arsenal Medical, Inc. Articles et procédés pour la réparation de tissus
US8844158B2 (en) * 2008-12-19 2014-09-30 Iqtex Patentverwaltung Ug Super absorber polymer felt and method for the production thereof
US20110125183A1 (en) * 2009-11-24 2011-05-26 Circaid Medical Products Graduated Compression Device for the Treatment of Circulatory Disorders
US20140236112A1 (en) * 2011-09-26 2014-08-21 Bsn Medical Gmbh Wound dressing
WO2013059600A1 (fr) * 2011-10-20 2013-04-25 Eaves Felmont Revêtement amovible et emballage interactif
US20130123728A1 (en) * 2011-11-15 2013-05-16 Kci Licensing, Inc. Medical dressings, systems, and methods with thermally-enhanced vapor transmissions
US20150119833A1 (en) * 2013-10-30 2015-04-30 Kci Licensing, Inc. Dressing with differentially sized perforations
US20170367899A1 (en) * 2015-01-19 2017-12-28 Presscise Ab A compression garment for provision of an adjustable pressure
WO2017214090A1 (fr) * 2016-06-06 2017-12-14 Elwha Llc Systèmes et procédés de surveillance de la compression à l'aide de bandages de compression à éléments électroniques étirables

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11628093B2 (en) 2008-05-08 2023-04-18 Convatec Technologies, Inc. Wound dressing
US11458044B2 (en) 2008-09-29 2022-10-04 Convatec Technologies Inc. Wound dressing
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
US11241525B2 (en) 2010-12-08 2022-02-08 Convatec Technologies Inc. Wound exudate monitor accessory
US11116884B2 (en) 2010-12-08 2021-09-14 Convatec Technologies Inc. Integrated system for assessing wound exudates
US11583430B2 (en) 2011-09-02 2023-02-21 Convatec Ltd. Skin contact material
US11241339B2 (en) 2011-11-29 2022-02-08 Convatec Inc. Perforated binder for laminated wound dressing
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres
US11723808B2 (en) 2016-03-30 2023-08-15 Convatec Technologies Inc. Detecting microbial infections in wounds
US11740241B2 (en) 2016-03-30 2023-08-29 Synovo Gmbh Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds
US11266774B2 (en) 2016-07-08 2022-03-08 Convatec Technologies Inc. Fluid collection apparatus
US11452808B2 (en) 2016-07-08 2022-09-27 Convatec Technologies Inc. Fluid flow sensing
US11596554B2 (en) 2016-07-08 2023-03-07 Convatec Technologies Inc. Flexible negative pressure system
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems
WO2021188185A1 (fr) * 2020-03-18 2021-09-23 Compression Dynamics, LLC Vêtements, kits, systèmes et procédés de pansement

Similar Documents

Publication Publication Date Title
WO2020014310A1 (fr) Pansement avancé ayant une compression et une manipulation de fluide totale accrue
EP3829504B1 (fr) Pansement souple et conformable pour plaie à capacité d'absorption de fluide améliorée
US20200000642A1 (en) Multilayer absorbent dressing construction
US20200093646A1 (en) Super-absorbent, low trauma, advanced wound dressing
US20180064843A1 (en) Wound dressing
EP3917474B1 (fr) Pansement de plaie partiellement transparent
WO2018226592A1 (fr) Pansement pour plaie avec absorption d'odeurs et transmission accrue de vapeur d'humidité
US10940050B2 (en) Wound dressing assembly
US10034799B2 (en) Two-stage wound dressing assembly
US20220313493A1 (en) Wound Dressing Construct With High Wicking Adhesive Border
US20220296435A1 (en) Novel Absorbent Wound Dressing Construct That Allows Wound Fluid Assessment In Use
US20240016974A1 (en) Transparent dressing with hydrogel layer
KR200359390Y1 (ko) 의료용 패치
US20210401627A1 (en) Super-absorbent advanced wound dressing with dressing full indication
WO2024064336A1 (fr) Pansement transparent avec couche d'hydrogel
GB2455984A (en) Wound dressing kit
KR20110010888U (ko) 드레싱용 히드로겔 롤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19745519

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19745519

Country of ref document: EP

Kind code of ref document: A1